Flexivue Microlens

About Presbia

Presbia's mission is to commercialize a surgical solution for presbyopia, the age-related loss of near vision affecting over 1.8 billion people. Its core achievement is the development and CE Mark approval of the Flexivue Microlens, a proprietary corneal inlay implant. The company's strategy has historically focused on securing regulatory approval in key markets like the US and Europe, though recent years have been defined by financial challenges, delisting, and a shift towards restructuring and seeking strategic alternatives to monetize its technology platform.

About Presbia

Presbia's mission is to commercialize a surgical solution for presbyopia, the age-related loss of near vision affecting over 1.8 billion people. Its core achievement is the development and CE Mark approval of the Flexivue Microlens, a proprietary corneal inlay implant. The company's strategy has historically focused on securing regulatory approval in key markets like the US and Europe, though recent years have been defined by financial challenges, delisting, and a shift towards restructuring and seeking strategic alternatives to monetize its technology platform.

Therapeutic Areas